胰腺癌诊治的进展与思考

刘悦泽; 张太平; 赵玉沛

doi:10.12449/JCH250401

胰腺癌诊治的进展与思考

DOI: 10.12449/JCH250401

中国医学科学院北京协和医院基本外科，北京 100005

基金项目:

中央高校基本科研业务费专项资金 (3332024117)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：刘悦泽负责查阅文献，撰写文章；张太平负责起草文章大纲，审阅修改文章；赵玉沛负责基金支持，审阅修改文章。

详细信息

通信作者:
赵玉沛， zhao8028@263.com （ORCID： 0000-0001-7081-2299）

计量
- 文章访问数: 256
- HTML全文浏览量: 72
- PDF下载量: 110
- 被引次数: 0
出版历程
- 收稿日期: 2025-02-11
- 录用日期: 2025-02-21
- 出版日期: 2025-04-25

Advances and thoughts in the diagnosis and treatment of pancreatic cancer

Department of General Surgery，Peking Union Medical College Hospital，Chinese Academy of Medical Sciences，Beijing 100005，China

Research funding:

Fundamental Research Funds for the Central Universities (3332024117)

More Information

Corresponding author: ZHAO Yupei， zhao8028@263.com （ORCID： 0000-0001-7081-2299）

摘要

摘要: 近年来，胰腺癌的规范化诊治已经在我国取得了长足的进步和发展。从最初的治疗手段匮乏，药物效果不佳，到如今手术、化疗、放疗、免疫与靶向治疗齐头并进，多学科共同决策的综合治疗模式，胰腺癌诊治逐步走向个体化、精细化与精准化。本文就胰腺癌诊治中的热点话题，结合最新的循证医学证据，探讨胰腺癌诊治的未来发展方向。
- 胰腺肿瘤 /
- 诊断 /
- 治疗学
Abstract: In recent years， significant progress has been made in the standardized diagnosis and treatment of pancreatic cancer in China. From the lack of treatment options and poor drug efficacy at the beginning to the current comprehensive treatment modality integrating surgery， chemotherapy， radiotherapy， immunotherapy， and targeted therapy under multidisciplinary decision-making， the diagnosis and treatment of pancreatic cancer has gradually achieved higher levels of individualization， refinement， and precision. With reference to the latest evidence-based medical data， this article discusses the hot topics in the diagnosis and treatment of pancreatic cancer and explores the future development directions of this field.
- Pancreatic Neoplasms /
- Diagnosis /
- Therapeutics

HTML全文

参考文献(23)

[1]	SIEGEL RL, GIAQUINTO AN, JEMAL A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74( 1): 12- 49. DOI: 10.3322/caac.21820.
[2]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66( 2): 115- 132. DOI: 10.3322/caac.21338.
[3]	CUI JJ, FU QH, CHEN XB, et al. The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China[J]. J Pancreatol, 2023, 7: 1- 9. DOI: 10.1097/JP9.0000000000000155.
[4]	CAO K, XIA YD, YAO JW, et al. Large-scale pancreatic cancer detection via non-contrast CT and deep learning[J]. Nat Med, 2023, 29: 3033- 3043. DOI: 10.1038/s41591-023-02640-w.
[5]	Pancreatic Surgery Group, Surgery Branch of Chinese Medical Association; Professional Committee of Pancreatic Diseases, Chinese Research Hospital Association. The guideline for neoadjuvant therapy of pancreatic cancer in China(2020 edition)[J]. Med J Peking Union Med Coll Hosp, 2020, 11( 5): 547- 558. DOI: 10.3969/j.issn.1674-9081.2020.05.010. 中华医学会外科学分会胰腺外科学组, 中国研究型医院学会胰腺疾病专业委员会. 中国胰腺癌新辅助治疗指南(2020版)[J]. 协和医学杂志, 2020, 11( 5): 547- 558. DOI: 10.3969/j.issn.1674-9081.2020.05.010.
[6]	ZHANG TP, LIU YZ, REN B. Current status and challenges of total neoadjuvant therapy for pancreatic cancer[J]. Chin J Dig Surg, 2022, 21( 4): 461- 464. DOI: 10.3760/cma.j.cn115610-20220320-00141. 张太平, 刘悦泽, 任博. 胰腺癌全程新辅助治疗的现状及挑战[J]. 中华消化外科杂志, 2022, 21( 4): 461- 464. DOI: 10.3760/cma.j.cn115610-20220320-00141.
[7]	WANG M, LI DW, CHEN RF, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: A multicentre, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2021, 6( 6): 438- 447. DOI: 10.1016/S2468-1253(21)00054-6.
[8]	WANG M, PENG B, LIU JH, et al. Practice patterns and perioperative outcomes of laparoscopic pancreaticoduodenectomy in China: A retrospective multicenter analysis of 1 029 patients[J]. Ann Surg, 2021, 273( 1): 145- 153. DOI: 10.1097/SLA.0000000000003190.
[9]	SHI YS, WANG WS, QIU WH, et al. Learning curve from 450 cases of robot-assisted pancreaticoduocectomy in a high-volume pancreatic center: Optimization of operative procedure and a retrospective study[J]. Ann Surg, 2021, 274( 6): e1277- e1283. DOI: 10.1097/SLA.0000000000003664.
[10]	WANG W, LOU W, XU Z, et al. Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospective randomized controlled trial[J]. J Adv Res, 2023, 49: 151- 157. DOI: 10.1016/j.jare.2022.09.011.
[11]	KHACHFE HH, NASSOUR I, HAMMAD AY, et al. Robotic pancreaticoduodenectomy: increased adoption and improved outcomes: is laparoscopy still justified?[J] Ann Surg, 2023, 278( 3): e563- e569. DOI: 10.1097/SLA.0000000000005687.
[12]	ZWART MJW, van den BROEK B, DE GRAAF N, et al. The feasibility, proficiency, and mastery learning curves in 635 robotic pancreatoduodenectomies following a multicenter training program:“standing on the shoulders of giants”[J]. Ann Surg, 2023, 278( 6): e1232- e1241. DOI: 10.1097/sla.0000000000005928.
[13]	WU WM, MIAO Y, YANG YM, et al. Real-world study of surgical treatment of pancreatic cancer in China: Annual report of China Pancreas Data Center(2016—2020)[J]. J Pancreatol, 2022, 5( 1): 1- 9. DOI: 10.1097/jp9.0000000000000086.
[14]	WAINBERG ZA, MELISI D, MACARULLA T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma(NAPOLI 3): A randomised, open-label, phase 3 trial[J]. Lancet, 2023, 402( 10409): 1272- 1281. DOI: 10.1016/s0140-6736(23)01366-1.
[15]	QIN S, LI J, BAI Y, et al. Nimotuzumab plus gemcitabine for K-ras wild-type locally advanced or metastatic pancreatic cancer[J]. J Clin Oncol, 2023, 41( 33): 5163- 5173. DOI: 10.1200/jco.22.02630.
[16]	STRICKLER JH, SATAKE H, GEORGE TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388( 1): 33- 43. DOI: 10.1056/NEJMoa2208470.
[17]	KEMP SB, CHENG N, MARKOSYAN N, et al. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer[J]. Cancer Discov, 2023, 13( 2): 298- 311. DOI: 10.1158/2159-8290.CD-22-1066.
[18]	QI C, LIU C, GONG J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results[J]. Nat Med, 2024, 30( 8): 2224- 2234. DOI: 10.1038/s41591-024-03037-z.
[19]	PISHVAIAN MJ, BLAIS EM, BRODY JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial[J]. Lancet Oncol, 2020, 21( 4): 508- 518. DOI: 10.1016/S1470-2045(20)30074-7.
[20]	AGUIRRE AJ, NOWAK JA, CAMARDA ND, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine[J]. Cancer Discov, 2018, 8( 9): 1096- 1111. DOI: 10.1158/2159-8290.CD-18-0275.
[21]	BAILEY P, CHANG DK, NONES K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531( 7592): 47- 52. DOI: 10.1038/nature16965.
[22]	DREYER SB, UPSTILL-GODDARD R, LEGRINI A, et al. Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence[J]. Gastroenterology, 2022, 162( 1): 320- 324. e 4. DOI: 10.1053/j.gastro.2021.09.022.
[23]	LOWERY MA, JORDAN EJ, BASTURK O, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: Potential actionability and correlation with clinical phenotype[J]. Clin Cancer Res, 2017, 23( 20): 6094- 6100. DOI: 10.1158/1078-0432.CCR-17-0899.